Clinical trials: Blood Plasma Therapy
Multiple Myeloma, Relapsed Cancer
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease
- Trial name
- NCT05641324
- Testing
- ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 4 people
- Sponsor
- Anaveon AG
Atypical Hemolytic Uremic Syndrome
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).
- Trial name
- aHUS (NCT00838513)
- Testing
- eculizumab
- Where
- 13 sites in Canada, France and 5 more
- Volunteers
- 15 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Foot Ulcers, Diabetic
Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease
This study is a randomized clinical trial that compares the effectiveness of Plasma Rich in Growth Factors (PRGF) with conventional treatment for healing foot ulcers in diabetic patients who also have peripheral arterial disease.
- Trial name
- PIEDIABETICO (NCT06952998)
- Testing
- Topical application of Plasma Rich in Growth Factors (PRGF), Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Biotechnology Institute IMASD
Wrinkles, Acne Scars
Fractional Ablative Radiofrequency for the Treatment of Acne Scars and Wrinkles
To assess the safety and efficacy of the Pixel RF (fractional radio frequency) module in the treatment of acne scars and wrinkles.
- Trial name
- NCT01645345
- Testing
- Alma Lasers Accent RF Pixel handpiece
- Where
- 3 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Acute Myeloid Leukemia, Multiple Myeloma
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
- Trial name
- NCT04097301
- Testing
- MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
- Where
- 3 sites in Czechia, Italy
- Volunteers
- 8 people
- Sponsor
- AGC Biologics S.p.A.
Multiple Myeloma
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of NOX A12 alone and in combination with a background therapy of bortezomib and dexamethasone (VD) chemotherapy in previously treated patients with multiple myeloma…
- Trial name
- NCT01521533
- Testing
- NOX-A12
- Where
- 10 sites in Austria, France and 2 more
- Volunteers
- 28 people
- Sponsor
- TME Pharma AG
Multiple Myeloma
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® [bortezomib] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
- Trial name
- NCT00555906
- Testing
- Bortezomib, Dexamethasone, PD 0332991
- Where
- 19 sites in United States, Czechia and 1 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Multiple Myeloma
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM).
- Trial name
- NCT03785184
- Testing
- venetoclax, lenalidomide, dexamethasone
- Where
- 22 sites in United States, Australia and 2 more
- Sponsor
- AbbVie
Multiple Myeloma
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose (MTD) of pomalidomide in combination with bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma
- Trial name
- NCT01497093
- Testing
- Pomalidomide, Bortezomib, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur.
- Trial name
- iinnovate-1 (NCT03215030)
- Testing
- Modakafusp alfa, Dexamethasone
- Where
- 94 sites in United States, Canada and 14 more
- Volunteers
- 272 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Multiple Myeloma
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with…
- Trial name
- LINKER-MM4 (NCT05828511)
- Testing
- Linvoseltamab
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 149 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Refractory Multiple Myeloma
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data.
- Trial name
- NCT05053607
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pack Health
Multiple Myeloma
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab…
- Trial name
- MAGNETISMM-5 (NCT05020236)
- Testing
- Elranatamab, Daratumumab, Pomalidomide
- Where
- 237 sites in United States, Argentina and 24 more
- Volunteers
- 893 people
- Sponsor
- Pfizer
Multiple Myeloma
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-3 (NCT06235229)
- Testing
- GC012F
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
Multiple Myeloma
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
- Trial name
- MonumenTAL-8 (NCT06550895)
- Testing
- Cilta-cel, Talquetamab
- Where
- 9 sites in United States, Australia
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Enzyme products such as Wobe-Mugos E may help to reduce the side effects of multiple myeloma therapy.
- Trial name
- NCT00014339
- Testing
- Wobe-Mugos E, melphalan, prednisone
- Where
- 19 sites in United States
- Sponsor
- Medsearch
Hematological Malignancy, Leukemia
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
The purpose of this study is to determine the safety and anti-tumor effects of an experimental immunotherapy drug, called AlloStim, which is intentionally mis-matched immune cells which are designed to elicit the same anti-tumor…
- Conditions
- Hematological Malignancy, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00558675
- Testing
- AlloStim
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Mirror Biologics, Inc.
Knee Osteoarthritis, Knee Osteoarthritis (Knee OA)
Efficacy of Platelet-Rich Plasma Combined With Hyaluronic Acid in Knee Osteoarthritis
This prospective, randomized, open-label, single-centre post-market clinical follow-up (PMCF) study evaluates the clinical performance and safety of a single intra-articular injection of hyaluronic acid (HA) combined with…
- Conditions
- Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA), Osteoarthritis (OA) of the Knee
- Trial name
- NCT07784907
- Testing
- Hyaluronic Acid (HA) and Platelet rich plasma (PRP), Hyaluronic Acid (HA)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Implai Sp z o.o
Relapsed/Refractory Multiple Myeloma
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine…
- Trial name
- NCT05000450
- Testing
- ALLO-605, ALLO-647, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Allogene Therapeutics
Primary Hypercholesterolaemia
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance.
- Trial name
- NCT00396240
- Testing
- Rosuvastatin, Initiatives to improve compliance
- Volunteers
- 1,294 people
- Sponsor
- AstraZeneca